EMA Authorised: Erbitux (cetuximab) — Merck Europe B.V.

View source ↗

Summary

Erbitux (cetuximab) has been authorised by EMA for therapeutic areas including head and neck neoplasms and colorectal neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Head and Neck Neoplasms

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Status: Authorised. Therapeutic area: Head and Neck Neoplasms;Colorectal Neoplasms. MAH: Merck Europe B.V.. Decision date: 25/06/2026